Literature DB >> 35013536

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.

Laure Vincent1, Luuk Gras2, Patrice Ceballos3, Jürgen Finke4, Jakob Passweg5, Stéphanie Harel6, Laura Rosinol7, Monique Minnema8, Raphael Teipel9, Jaap van Doesum10, Mathias Hänel11, Pascal Lenain12, Carmen Botella-Garcia13, Christian Koenecke14, Sophie Ducastelle15, Jaime Sanz16, Wilfried Schroyens17, Tsila Zuckerman18, Federico Monaco19, Linda Koster20, Liesbeth de Wreede21, Patrick J Hayden22, Stefan Schönland23, Ibrahim Yakoub-Agha24, Meral Beksac25.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35013536     DOI: 10.1038/s41409-021-01560-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  1 in total

Review 1.  Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Jean-Sébastien Claveau; Francis K Buadi; Shaji Kumar
Journal:  Oncol Ther       Date:  2022-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.